NCT03601455 2025-04-13
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT03871036 2025-03-06
ICRA
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03317158 2025-01-30
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT03518606 2025-01-15
MOVIE
UNICANCER
Phase 1/2 Completed
NCT03702179 2024-12-05
IMMUNOPRESERVE
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02819596 2024-11-04
CALYPSO
Queen Mary University of London
Phase 2 Completed
NCT03204812 2024-10-15
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03557918 2024-07-03
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT02762006 2024-03-18
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT05120622 2023-10-31
Rideau
University of British Columbia
Phase 1/2 Withdrawn
NCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01975831 2022-10-12
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02626130 2022-07-07
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT03430895 2021-12-01
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03081923 2021-05-14
APACHE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT03288532 2020-09-07
RAMPART
University College, London
Phase 3 Recruiting
NCT03598816 2020-08-13
PIVOT-RCC
Washington University School of Medicine
Phase 2 Withdrawn
NCT04073160 2020-07-07
TRIO Bladder
Duke University
Phase 1 Withdrawn
NCT03234153 2020-06-17
NITIMIB
Insel Gruppe AG, University Hospital Bern
Phase 2 Terminated
NCT00702923 2019-11-21
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
University of Wisconsin, Madison
Phase 1 Terminated
NCT00880854 2019-11-15
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
University of Wisconsin, Madison
Phase 1 Withdrawn
NCT03150836 2017-10-19
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco
Phase 2 Withdrawn